Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$45,820 Mln
Revenue (TTM)
$4,304 Mln
Net Profit (TTM)
$1,059 Mln
ROE
0.7 %
ROCE
46.6 %
P/E Ratio
43.9
P/B Ratio
28.5
Industry P/E
--
EV/EBITDA
30.8
Div. Yield
0 %
Debt to Equity
0.7
Book Value
$19.9
EPS
$13.1
Face value
--
Shares outstanding
79,624,034
CFO
$4,872.40 Mln
EBITDA
$6,702.20 Mln
Net Profit
$4,514.68 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
IDEXX Laboratories (IDXX)
| -14.7 | -7.8 | -17.0 | 36.6 | 7.0 | 2.7 | 22.7 |
|
BSE Sensex*
| -12.6 | -11.7 | -12.4 | -1.8 | 8.4 | 8.5 | 11.5 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
IDEXX Laboratories (IDXX)
| 63.6 | -25.3 | 36.1 | -38.0 | 31.7 | 91.4 | 40.4 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
IDEXX Laboratories (IDXX)
|
577.1 | 45,820.3 | 4,303.7 | 1,059.5 | 31.7 | 66.2 | 43.9 | 28.5 |
| 108.5 | 187,721.9 | 44,328.0 | 6,524.0 | 20.0 | 13.1 | 29 | 3.6 | |
| 158.1 | 57,735.4 | 21,923.0 | 1,757.0 | 12.0 | 6.9 | 26 | 1.8 | |
| 71.3 | 102,581.0 | 20,074.0 | 2,886.0 | 14.7 | 12.5 | 35.6 | 4.2 | |
| 191.5 | 132,461.4 | 24,568.0 | 3,614.0 | 18.3 | 7.1 | 37.2 | 2.9 | |
| 82.6 | 47,515.3 | 6,067.6 | 1,073.5 | 20.4 | 10.6 | 45.2 | 4.8 | |
| 477.7 | 167,678.3 | 10,064.7 | 2,856.0 | 29.3 | 16.7 | 59.8 | 9.5 | |
| 227.9 | 33,694.9 | 5,398.1 | 1,485.9 | 34.0 | 24.2 | 22.8 | 5.3 | |
| 345.8 | 128,878.1 | 25,116.0 | 3,246.0 | 17.9 | 15.1 | 40.1 | 5.8 | |
| 464.7 | 172,506.1 | 44,556.0 | 6,737.0 | 19.5 | 13.1 | 26.2 | 3.3 |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments:... Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine. Read more
President, CEO & Director
Mr. Jonathan J. Mazelsky
President, CEO & Director
Mr. Jonathan J. Mazelsky
Headquarters
Westbrook, ME
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of IDEXX Laboratories Inc (IDXX) is $577.12 (NASDAQ) as of 18-Mar-2026 16:00 EDT. IDEXX Laboratories Inc (IDXX) has given a return of 6.98% in the last 3 years.
The P/E ratio of IDEXX Laboratories Inc (IDXX) is 43.87 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
51.52
|
34.00
|
|
2024
|
38.68
|
21.52
|
|
2023
|
55.13
|
31.38
|
|
2022
|
50.35
|
56.17
|
|
2021
|
76.15
|
82.21
|
The 52-week high and low of IDEXX Laboratories Inc (IDXX) are Rs 769.98 and Rs 356.25 as of 19-Mar-2026.
IDEXX Laboratories Inc (IDXX) has a market capitalisation of $ 45,820 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in IDEXX Laboratories Inc (IDXX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-9.86
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.